Enterprise Value
104.7M
Cash
477M
Avg Qtr Burn
-27.26M
Short % of Float
14.67%
Insider Ownership
1.76%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tipifarnib Details Head and neck cancer, Cancer, Head and neck squamous cell carcinoma | Phase 2 Data readout | |
Tipifarnib Details Cancer, T-cell lymphoma, Lymphoma | Phase 2 Update | |
Ziftomenib (menin inhibitor) (KO-539) Details Acute myeloid leukemia | Phase 2 Update | |
Tipifarnib + alpelisib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update | |
KO-2806 (FTI inhibitor) Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Data readout | |
Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin Details Blood cancer, Acute myeloid leukemia | Phase 1 Data readout | |
KO-2806 (FTI inhibitor) + cabozantinib Details Solid tumor/s, Renal cell carcinoma | Phase 1 Initiation | |
Ziftomenib + gilteritinib Details Acute myeloid leukemia | Phase 1 Initiation |